A theme involving the development of therapeutics based on proprietary technology in the United States, Europe and Japan, acquisition of orphan-drug designations, and overseas out-licensing through a business and capital alliance with JCR Pharma and its conversion into an equity-method affiliate. It covers drug discovery and overseas commercialization based on the capital relationship, including preparations to establish a joint venture and a joint development agreement in Japan.